Thomas A Mavrakanas1,2,3, Omer Kamal4, David M Charytan4,5. 1. Renal Division, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts thomas.mavrakanas@mcgill.ca. 2. Department of Medicine, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland. 3. Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada. 4. Renal Division, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts. 5. Division of Nephrology, New York University Grossman School of Medicine, New York, New York.
Abstract
BACKGROUND AND OBJECTIVES: Prasugrel and ticagrelor have superior efficacy compared with clopidogrel in moderate CKD but have not been studied in kidney failure. The study objective is to determine the effectiveness and safety of prasugrel and ticagrelor in kidney failure. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This retrospective cohort study used United States Renal Data System data from 2012 to 2015. We identified all patients on dialysis who received a drug-eluting stent and were alive at 90 days after stent implantation. Inverse probability-weighted Cox proportional hazard models were used. Weights were estimated with propensity scores for multiple treatments. RESULTS: This cohort included 6648 patients on clopidogrel, 621 on prasugrel, and 449 on ticagrelor. A total of 3279 primary composite (cardiovascular death, myocardial infarction, or stroke) and 2120 clinically relevant bleeding events were observed. The incidence of the primary composite outcome of cardiovascular death, myocardial infarction, or stroke at 12 months was similar across the three treatment groups. The absolute event rate in the unweighted cohort was 144 events per 100 patient-years for clopidogrel, 126 for prasugrel, and 161 for ticagrelor. For prasugrel versus clopidogrel, the weighted hazard ratio was 0.96 (95% confidence interval, 0.82 to 1.11; P=0.58). For ticagrelor versus clopidogrel, the hazard ratio was 1.00 (95% confidence interval, 0.83 to 1.20; P=0.98). A numerically higher incidence of clinically relevant bleeding was seen with prasugrel or ticagrelor compared with clopidogrel (weighted hazard ratio, 1.15; 95% confidence interval, 0.95 to 1.38 and weighted hazard ratio, 1.13; 95% confidence interval, 0.91 to 1.40, respectively). CONCLUSIONS: Prasugrel or ticagrelor does not seem to be associated with significant benefits compared with clopidogrel in patients with kidney failure treated with drug-eluting stents. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2021_04_02_CJN12120720.mp3.
BACKGROUND AND OBJECTIVES: Prasugrel and ticagrelor have superior efficacy compared with clopidogrel in moderate CKD but have not been studied in kidney failure. The study objective is to determine the effectiveness and safety of prasugrel and ticagrelor in kidney failure. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This retrospective cohort study used United States Renal Data System data from 2012 to 2015. We identified all patients on dialysis who received a drug-eluting stent and were alive at 90 days after stent implantation. Inverse probability-weighted Cox proportional hazard models were used. Weights were estimated with propensity scores for multiple treatments. RESULTS: This cohort included 6648 patients on clopidogrel, 621 on prasugrel, and 449 on ticagrelor. A total of 3279 primary composite (cardiovascular death, myocardial infarction, or stroke) and 2120 clinically relevant bleeding events were observed. The incidence of the primary composite outcome of cardiovascular death, myocardial infarction, or stroke at 12 months was similar across the three treatment groups. The absolute event rate in the unweighted cohort was 144 events per 100 patient-years for clopidogrel, 126 for prasugrel, and 161 for ticagrelor. For prasugrel versus clopidogrel, the weighted hazard ratio was 0.96 (95% confidence interval, 0.82 to 1.11; P=0.58). For ticagrelor versus clopidogrel, the hazard ratio was 1.00 (95% confidence interval, 0.83 to 1.20; P=0.98). A numerically higher incidence of clinically relevant bleeding was seen with prasugrel or ticagrelor compared with clopidogrel (weighted hazard ratio, 1.15; 95% confidence interval, 0.95 to 1.38 and weighted hazard ratio, 1.13; 95% confidence interval, 0.91 to 1.40, respectively). CONCLUSIONS: Prasugrel or ticagrelor does not seem to be associated with significant benefits compared with clopidogrel in patients with kidney failure treated with drug-eluting stents. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2021_04_02_CJN12120720.mp3.
Authors: S T Normand; M B Landrum; E Guadagnoli; J Z Ayanian; T J Ryan; P D Cleary; B J McNeil Journal: J Clin Epidemiol Date: 2001-04 Impact factor: 6.437
Authors: Robert Edfors; Anders Sahlén; Karolina Szummer; Henrik Renlund; Marie Evans; Juan-Jesus Carrero; Jonas Spaak; Stefan K James; Bo Lagerqvist; Christoph Varenhorst; Tomas Jernberg Journal: Heart Date: 2018-03-24 Impact factor: 5.994
Authors: Usman Baber; Jaya Chandrasekhar; Samantha Sartori; Melissa Aquino; Annapoorna S Kini; Samir Kapadia; William Weintraub; Joseph B Muhlestein; Birgit Vogel; Michela Faggioni; Serdar Farhan; Sandra Weiss; Craig Strauss; Catalin Toma; Anthony DeFranco; Brian A Baker; Stuart Keller; Mark B Effron; Timothy D Henry; Sunil Rao; Stuart Pocock; George Dangas; Roxana Mehran Journal: JACC Cardiovasc Interv Date: 2017-08-02 Impact factor: 11.195
Authors: Stephen D Wiviott; Eugene Braunwald; Carolyn H McCabe; Gilles Montalescot; Witold Ruzyllo; Shmuel Gottlieb; Franz-Joseph Neumann; Diego Ardissino; Stefano De Servi; Sabina A Murphy; Jeffrey Riesmeyer; Govinda Weerakkody; C Michael Gibson; Elliott M Antman Journal: N Engl J Med Date: 2007-11-04 Impact factor: 91.245
Authors: Lars Wallentin; Richard C Becker; Andrzej Budaj; Christopher P Cannon; Håkan Emanuelsson; Claes Held; Jay Horrow; Steen Husted; Stefan James; Hugo Katus; Kenneth W Mahaffey; Benjamin M Scirica; Allan Skene; Philippe Gabriel Steg; Robert F Storey; Robert A Harrington; Anneli Freij; Mona Thorsén Journal: N Engl J Med Date: 2009-08-30 Impact factor: 91.245
Authors: Daniel F McCaffrey; Beth Ann Griffin; Daniel Almirall; Mary Ellen Slaughter; Rajeev Ramchand; Lane F Burgette Journal: Stat Med Date: 2013-03-18 Impact factor: 2.373
Authors: Constance C F M J Baaten; Jonas R Schröer; Jürgen Floege; Nikolaus Marx; Joachim Jankowski; Martin Berger; Heidi Noels Journal: Clin J Am Soc Nephrol Date: 2021-11-08 Impact factor: 8.237
Authors: Nishank Jain; Bradley C Martin; Junqiang Dai; Milind A Phadnis; Layth Al-Hindi; Theresa I Shireman; S Susan Hedayati; Rafia S Rasu; Jawahar L Mehta Journal: Kidney360 Date: 2022-05-18
Authors: Nishank Jain; Milind A Phadnis; Suzanne L Hunt; Junqiang Dai; Theresa I Shireman; Clayton L Davis; Jawahar L Mehta; Rafia S Rasu; S Susan Hedayati Journal: Kidney Int Rep Date: 2021-07-03